AI assistant
Coloplast — Proxy Solicitation & Information Statement 2010
Nov 30, 2010
3358_mrq_2010-11-30_bd12a832-1d51-4ec7-b049-9a64db5d2455.pdf
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
Announcement No. 15/2010 30 November 2010
Notification of proxies received by the Board of Directors
Pursuant to section 29 of the Danish Securities Trading Act, cf. section 4(viii), cf. section 5(3), of the executive order on major shareholders, Coloplast A/S announces that the company's Board of Directors has received proxies from a number of shareholders to vote on their behalf at the annual general meeting to be held on 1 December 2010.
Coloplast's Board of Directors has received proxies as a result of which the Board of Directors has at its disposal votes equivalent to more than 5% of the total voting rights at the annual general meeting.
Accordingly, as of today, the Board of Directors has proxies in respect of 8.41% of the voting rights and of the company's total share capital.
After the close of the annual general meeting on 1 December 2010, the Board of Directors' authority to vote under the proxies received will lapse.
Lene Skole Executive Vice President, CFO
For further information, please contact
Investors and analysts
Lene Skole Executive Vice President, CFO Tel. +45 4911 1700
Ian S.E. Christensen Director of Investor Relations Tel. +45 4911 1800/+45 4911 1301 Email: [email protected]
Henrik Nord Investor Relations Manager Tel. +45 4911 1800/+45 4911 3108 Email: [email protected]
Press and the media
Ulla Lundhus Media Relations Manager Tel. +45 4911 1929 Email: [email protected]
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2010-11 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.
Our business includes Ostomy Care, Urology and Continence Care and Wound and Skin Care. We operate globally and employ more than 7,000 people.